Colorectal cancer is a carcinoma arising from the luminal surface of the colon.
It is the 2nd most common cancer in women and third most common cancer in male worldwide. It commonly arises from adenomatous polyps.
It is strongly linked to age with 83% occurring in people ≥60 years old.
Rectal cancer is defined as cancerous lesions located within 12 cm of the anal verge.
A faecal immunochemical test (FIT) is able to accurately rule out colorectal cancer (CRC) and is as sensitive as colonoscopy, the current gold standard for CRC diagnosis, the NICE* FIT study has shown.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
The use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be associated with a reduced risk of colorectal cancer (CRC), according to a retrospective cohort study from Hong Kong.
A lower baseline carcinoembryonic antigen (CEA) is associated with better overall survival (OS) in patients receiving treatment with encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic CRC (mCRC), according to a subanalysis of BEACON CRC presented during the 2020 ESMO GI Meeting.
Paediatric-onset inflammatory bowel disease (IBD) carries a doubled risk of developing cancer later in life, with skin, lymphoid, and gastrointestinal tumours of a particular concern, a study has found. The risk is higher in males and independent of IBD subtype and medical treatment.
Patients with any subtypes of polyps had a greater risk of developing colorectal cancer (CRC) than the general population in a largely screening-naive Swedish cohort, indicating that CRC risk is not limited to just those with advanced histology, reveals a large registry-based study.
In addition to survival benefit, the BEACON CRC trial has now shown that a targeted drug combination of encorafenib plus cetuximab with or without binimetinib led to longer maintenance of quality of life (QoL) for patients with BRAF V600E metastatic colorectal cancer (mCRC) compared with standard chemotherapy.
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.